Bayer announced on Thursday the start of a Phase II clinical trial to assess the efficacy of the AB-1002 gene therapy developed by its biotech subsidiary AskBio in the treatment of heart failure.

The German group reports that it has enrolled the first patients in this trial, which is expected to enroll between 90 and 150 individuals in total, and will be conducted over 52 weeks in the United States and Europe.

Congestive heart failure occurs when the heart is unable to pump blood efficiently enough to meet the body's needs, notably to supply sufficient oxygen to the organs, and is characterized by a slowing of blood flow out of the heart.

Copyright (c) 2024 CercleFinance.com. All rights reserved.